SEP363856

Phase 1Small molecule

Otsuka

SEP363856 is one of 66 small molecule programs targeting Narcolepsy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NarcolepsyActive, not recruiting

SchizophreniaActive, not recruiting

NarcolepsyPhase 1

Active, not recruiting

SchizophreniaPhase 1

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

4 2

Resotran

Takeda

Preclinical

1 3

Ozempic

Novo Nordisk

Preclinical

1 4

Zocor

OOrganon and Co

Preclinical

6 5

Depakote

Ibrance

Lunesta

3 8

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 9

Compazine

GGlaxo Dba Glaxosmithkline

Preclinical

1 10

Vivarin

HHikma Pharmaceuticals LLC

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia2 trials

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Completed· Otsuka logo

Otsuka·Phase 3·NCT04115319·305 enrolled

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Completed· Otsuka logo

Otsuka·Phase 1·NCT04369391·150 enrolled

Narcolepsy1 trial

This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation.

Completed· Otsuka logo

Otsuka·Phase 1·NCT05015673·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SEP363856. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SEP363856 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SEP363856. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Otsuka

SEP363856

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia2 trials

Narcolepsy1 trial

References

Drug Info

Quick Facts

Related News